PainReform Ltd. (PRFX): Price and Financial Metrics

PainReform Ltd. (PRFX): $0.98

0.12 (-10.91%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

PRFX Price/Volume Stats

Current price $0.98 52-week high $26.41
Prev. close $1.10 52-week low $0.98
Day low $0.98 Volume 87,200
Day high $1.14 Avg. volume 116,426
50-day MA $1.89 Dividend yield N/A
200-day MA $3.36 Market Cap 1.69M

PRFX Stock Price Chart Interactive Chart >


PainReform Ltd. (PRFX) Company Bio


PainReform Ltd. operates as a pharmaceutical company. It develops and markets pharmaceuticals. The firm focuses on developing reformulation of pain therapeutics, PainReform applies its propriety formulation technologies to prolong and enhance efficacy, reduce adverse effects shortening recovery time and reduce the need of augmentation with drugs such as opioids and NSAIDS. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.


PRFX Latest News Stream


Event/Time News Detail
Loading, please wait...

PRFX Latest Social Stream


Loading social stream, please wait...

View Full PRFX Social Stream

Latest PRFX News From Around the Web

Below are the latest news stories about PAINREFORM LTD that investors may wish to consider to help them evaluate PRFX as an investment opportunity.

PainReform Provides Business Update for the Third Quarter of 2023

Reports enrollment of first patients for the second part of Phase 3 clinical trial in bunionectomyTEL AVIV, Israel, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the third quarter ended September 30, 2023. Ilan Hadar, Chief Executive Officer of PainReform, stated, "We are pleased to report a number of

Yahoo | November 15, 2023

PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File

Targeting to commence second part of Phase 3 clinical trial in mid-Q4 2023 Trial completion and results expected in mid-2024 TEL AVIV, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced plans to commence the second part of the Company’s phase 3 trial to evaluate PRF-110 in patients undergoing bunionectomy surgery. Star

Yahoo | September 11, 2023

PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary

Professor Eli Hazum to Share Positive Safety and PK Data of PRF-110 from First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy SurgeryTEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Company has been selected for a poster presentation, titled “Pharmacokinetics and Safety P

Yahoo | September 7, 2023

PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City

TEL AVIV, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform will be attending the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City. Mr. Hadar will be participating in one-

Yahoo | September 5, 2023

7 Stocks Under $10 to Buy for August

Stocks under $10 have many advantages, so it pays to see which has the best potential for growth.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | August 10, 2023

Read More 'PRFX' Stories Here

PRFX Price Returns

1-mo -46.74%
3-mo -56.30%
6-mo -61.26%
1-year -84.45%
3-year -96.84%
5-year N/A
YTD -64.36%
2023 -33.37%
2022 -68.97%
2021 -70.25%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!